Abstract
An inhibitory-effect of a selective cyclooxygenase-2 (COX-2) inhibitor on peritoneal metastasis of scirrhous gastric carcinoma was investigated in vivo. Peritoneal metastasis had developed after intraperitoneal inoculation of scirrhous gastric cancer cells, OCUM-2MD3, in nude mice. COX-2 inhibitor and/or S-1 were administered orally in nude mice with peritoneal metastasis. Oral administration of COX-2 inhibitor and S-1 significantly prolonged survival rates of these nude mice, compared with either alone. These findings suggested that combining S-1 and COX-2 inhibitor administration obtain a synergistic inhibitory-effect on the peritoneal metastasis of scirrhous gastric carcinoma.
MeSH terms
-
Adenocarcinoma, Scirrhous / drug therapy*
-
Adenocarcinoma, Scirrhous / secondary
-
Animals
-
Antimetabolites, Antineoplastic / therapeutic use
-
Benzenesulfonates / therapeutic use*
-
Cyclooxygenase 2 Inhibitors / therapeutic use*
-
Drug Combinations
-
Drug Synergism
-
Drug Therapy, Combination
-
Female
-
Humans
-
Mice
-
Mice, Inbred BALB C
-
Mice, Nude
-
Oxazoles / therapeutic use*
-
Oxonic Acid / therapeutic use*
-
Peritoneal Neoplasms / drug therapy*
-
Peritoneal Neoplasms / secondary
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / pathology
-
Survival Rate
-
Tegafur / therapeutic use*
-
Tumor Cells, Cultured
Substances
-
4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide
-
Antimetabolites, Antineoplastic
-
Benzenesulfonates
-
Cyclooxygenase 2 Inhibitors
-
Drug Combinations
-
Oxazoles
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid